Literature DB >> 10069355

Diagnosing polycythemia vera: a paradigm shift.

A Tefferi1.   

Abstract

The primary objective during the evaluation of erythrocytosis is to ascertain the presence or absence of polycythemia vera (PV). Because of prognostic and treatment differences, PV must be distinguished from relative polycythemia and secondary erythrocytosis. This distinction is currently accomplished through the laboratory measurement of red blood cell mass, plasma volume, and arterial oxygen saturation and determination of oxygen pressure at 50% hemoglobin saturation (P50). Furthermore, according to the Polycythemia Vera Study Group guidelines, the demonstration of an increased red blood cell mass is an absolute criterion for the diagnosis of PV. This article discusses the use of the serum erythropoietin level and endogenous erythroid colony assay as a potential alternative in the diagnosis of PV.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069355     DOI: 10.4065/74.2.159

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  5 in total

Review 1.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 2.  Rethinking the diagnostic criteria of polycythemia vera.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2013-12-19       Impact factor: 11.528

3.  New automated chemiluminescent assay for erythropoietin.

Authors:  E W Benson; R Hardy; C Chaffin; C A Robinson; R J Konrad
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

4.  Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions.

Authors:  Dmitry Abramov; Rose S Cohen; Stuart D Katz; Donna Mancini; Mathew S Maurer
Journal:  Am J Cardiol       Date:  2008-07-31       Impact factor: 2.778

5.  JAK2 mutation and acute coronary syndrome complicated with stent thrombosis.

Authors:  Toru Inami; Masahiro Okabe; Masato Matsushita; Nobuaki Kobayashi; Koiti Inokuchi; Noritake Hata; Yoshihiko Seino; Wataru Shimizu
Journal:  Heart Vessels       Date:  2016-01-29       Impact factor: 2.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.